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The genetic and phenotypic heterogeneity of autism spectrum disorders (ASD)
presents a substantial challenge for diagnosis, classification, research, and treatment.
Investigations into the underlying molecular etiology of ASD have often yielded mixed
and at times opposing findings. Defining the molecular and biochemical underpinnings
of heterogeneity in ASD is crucial to our understanding of the pathophysiological
development of the disorder, and has the potential to assist in diagnosis and the rational
design of clinical trials. In this review, we propose that genetically diverse forms of
ASD may be usefully parsed into entities resulting from converse patterns of growth
regulation at the molecular level, which lead to the correlates of general synaptic and
neural overgrowth or undergrowth. Abnormal brain growth during development is a
characteristic feature that has been observed both in children with autism and in mouse
models of autism. We review evidence from syndromic and non-syndromic ASD to
suggest that entities currently classified as autism may fundamentally differ by underlying
pro- or anti-growth abnormalities in key biochemical pathways, giving rise to either
excessive or reduced synaptic connectivity in affected brain regions. We posit that this
classification strategy has the potential not only to aid research efforts, but also to
ultimately facilitate early diagnosis and direct appropriate therapeutic interventions.
Keywords: autism spectrum disorders (ASD), neurotrophic factors, mTOR pathway, ERK signaling, MAP kinase
signaling system, protein synthesis
Introduction
Autism spectrum disorders (ASD) are a group of neurodevelopmental disorders frequently
characterized by impairments in social interactions, difficulties with language and communication,
and the presence of repetitive, perseverative behaviors (Abrahams and Geschwind, 2008; Zoghbi
and Bear, 2012). While ASD are generally highly heritable and can be defined by symptoms in
core areas, there exists significant heterogeneity in genetics, phenotypes, clinical presentation,
and associated comorbidities (Persico and Bourgeron, 2006). Recent advances have identified
hundreds of genetic risk factors, including common and rare genetic variants, which can increase
the likelihood of ASD (Ronemus et al., 2014). Many autism susceptibility genes are known to
have important roles in brain development, with functions ranging from synaptic transmission
to RNA processing and neurogenesis (Gilman et al., 2011; O’Roak et al., 2012; De Rubeis et al.,
2014). However, the plethora of genetic targets has highlighted the need for the ASD research
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community to understand whether genes implicated in ASD
may converge on common cellular and developmental processes
that can ultimately disrupt functions of brain circuits mediating
language, cognition, and social behavior.
Attempts have been previously made to stratify ASD patients
into smaller, more homogeneous subgroups by utilizing specific
genetic signatures (Bernier et al., 2014) or behavioral and
clinical endophenotypes (Spence et al., 2006; Eapen and Clarke,
2014). However, these strategies face difficulty encompassing
the genetic and phenotypic heterogeneity of ASD, and may not
assist in the identification of common neurobiological pathways
underlying disease. In this review, we propose that genetically
diverse forms of ASD may be usefully parsed into entities
resulting generally from either synaptic and neural overgrowth
or undergrowth, and the corresponding alterations in key
biochemical pathways supporting these phenotypes. We review
recent studies in patients and mouse models of ASD indicating
convergence toward these two fundamental biological processes
among genetically diverse causes of autism. We also discuss
potential molecular signaling pathways that may contribute to
these general alterations in growth and neural connectivity in
ASD. The review primarily emphasizes data reported from earlier
developmental stages to maintain a focus on alterations that
are potentially causal, rather than secondary results of ASD
pathology.
We propose that stratifying ASD based on readouts of over- or
under-growth is an informative approach for establishing a more
homogeneous sample. This will facilitate future research into the
mechanisms underlying autism pathogenesis. This approach also
has the potential to enable autism risk assessment, accelerate
progress in pre-clinical research and clinical trials to facilitate an
individualized approach to treatment, and avoid the discarding
of potentially useful therapeutic strategies. Figure 1 organizes
over- and under-growth phenotypes seen in ASD models and
patients, and pairs reviews and primary literature examining
these phenotypes.
Brain Growth, Structure, and Connectivity
in ASD
One of the earliest indications of aberrant brain growth
during development in ASD came from measurements of head
circumference among infants and young children with autism.
Head circumference is posited as a reliable proxy for relative
brain size during early postnatal ages (Bartholomeusz et al.,
2002). These studies have provided important initial evidence
for the presence of both over- and under-growth in ASD.
Many studies have shown head circumference to be abnormally
enlarged in children with ASD around the age of symptomatic
diagnosis (Courchesne et al., 2003, 2007). A study examining
126 autistic children (2–16 years of age) reported a higher
than expected incidence of both macrocephaly and microcephaly
(Fombonne et al., 1999).
Reciprocal changes in growth as grossly measured by head
size have also emerged as characteristic features of an increasing
number of syndromic and non-syndromic forms of ASD. For
example, de novo mutations in the dual-specificity tyrosine-
(Y)-phosphorylation-regulated kinase 1 A (DYRK1A) gene are
associated with a type of syndromic ASD and intellectual
disability that presents with microcephaly (Bronicki et al., 2015;
Van Bon et al., 2015). Conversely, macrocephaly has been shown
to occur in a subset of ASD patients harboring disruptive
mutations in the ASD-linked chromodomain helicase DNA
binding protein 8 (Chd8) gene or deletions in 17q12 (Moreno-
De-Luca et al., 2010; Bernier et al., 2014). This phenotype is
further discussed in the context of specific, genetically defined
causes of ASD later in this review. It is important to note that this
early pathology of dysregulated brain growth tends to normalize
later in childhood and adolescence, highlighting the necessity
to focus on alterations that occur during the critical periods of
prenatal and early postnatal development in ASD.
The application of neuroimaging methods to the study
of ASD has provided unprecedented insights into the
structure and intrinsic connectivity patterns of brain regions
involved in complex social behavior and cognition. Due to
technical constraints, previous assessments of functional brain
connectivity in ASD were limited to task-based activation studies
in adults with high-functioning autism, with relatively small
sample sizes and varied methodologies (reviewed in Müller et al.,
2011; Vissers et al., 2012). Brain changes observed in adulthood,
however, may not reflect primary aberrations and may not
generalize to children with severe low-functioning autism.
Notably, it is now also understood that lowered task-based
activation in fMRI could reflect cognitive performance deficits,
rather than an intrinsic property of brain function. Recent
studies have provided some clarification by taking advantage
of technical advancements in imaging and analysis to conduct
resting-state fMRI (R-fMRI) studies in younger ASD subject
populations in order to provide a more accurate model of the
developmental origins of the disease. These studies are useful
for an initial assessment of the feasibility of categorizing ASD by
over- or under-growth.
Supekar et al. (2013) and Keown et al. (2013) focused their
R-fMRI analyses to young children and adolescents with ASD
(7–14 years) to show increased long-range and short-range
intrinsic connectivity across multiple brain regions. Moreover,
the degree of functional hyperconnectivity was positively
correlated with severity of social and repetitive behavioral
symptoms (Keown et al., 2013; Supekar et al., 2013). Conversely,
decreased functional connectivity has been observed in long-
range interhemispheric projections and default mode networks
that typically exhibit greater activity under resting conditions as
opposed to tasks that require significant attention (Assaf et al.,
2010; Anderson et al., 2011; Anderson, 2014). In certain cases,
decreased functional connectivity has been inversely correlated
to severity of core behavioral deficits in ASD (Assaf et al., 2010).
Collectively, the fact that reciprocal changes in the intrinsic
functional architecture of the brain may result in phenotypic
outcomes associated with ASD supports the involvement of both
under- and over-growth mechanisms in ASD pathophysiology.
Recent work by Ellegood et al. has shown that mouse models
of ASD may be clustered in broad categories of brain under-
and over-connectivity, providing further support for parsing the
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FIGURE 1 | Model depicting a proposed classification of different subtypes of ASD based on correlates of growth state. Neural overgrowth and
undergrowth phenotypes have been associated with aberrant regulation of growth control pathways in autism spectrum disorders. Characteristic overgrowth and
(Continued)
Frontiers in Neuroscience | www.frontiersin.org 3 September 2015 | Volume 9 | Article 313
Subramanian et al. Growth regulatory pathways in ASDs
FIGURE 1 | Continued
undergrowth phenotypes can be observed consistently from molecular to cellular and network levels. (A) Upregulation of pro-growth pathways can lead to:
macrocephaly (Courchesne et al., 2003, 2007) aberrant overconnectivity of neuronal networks (Meikle et al., 2007; Keown et al., 2013; Supekar et al., 2013) increased
survival and proliferation at the cellular level (Castrén et al., 2005; Callan et al., 2010) increased synaptic growth at the subcellular level (Irwin et al., 2001; Jaworski
et al., 2005; Kwon et al., 2006; Tang et al., 2014), excessive protein synthesis (Osterweil et al., 2013; Santini et al., 2013) and/or a selective protein synthesis program
enhancing production of growth-promoting proteins. (B) In contrast, hypoactive growth pathways lead to microcephaly, (Bronicki et al., 2015; Van Bon et al., 2015)
underconnectivity of neuronal networks (Assaf et al., 2010; Anderson, 2014) decreased survival and proliferation at the cellular level (Yufune et al., 2015), decreased
synaptic growth at the subcellular level (Cheng et al., 2014), decreased protein synthesis (Li et al., 2013; Tian et al., 2015) and/or a protein synthesis program that
does not promote growth. These example phenotypes of undergrowth and overgrowth can be used as readouts for categorization of growth status in autism
spectrum disorders.
heterogeneity of ASD using this approach (Ellegood et al., 2015).
In patients, the majority of existing structural and neuroimaging
studies have focused on delineating the effects of age on intrinsic
connectivity patterns. As a result, while this approach holds
promise, we must await further work in order to assess whether
different genetic causes of autism may also classify into over-
or under-growth based on structural and functional measures of
brain connectivity.
Molecular Readouts of Growth
Mounting evidence has highlighted key growth signaling
pathways that are frequently perturbed in patients with ASD
as well as mouse models of autism. This section will cover
these key molecular readouts of growth in autism, including
dysregulated growth factor, mammalian target of rapamycin
(mTOR), and extracellular signal-regulated kinase (ERK1/2)
signaling. Characterizing how the regulators and downstream
correlates of these growth pathways are dysregulated in
ASD will allow us to better classify forms of autism into
broad, but more homogeneous subtypes. This knowledge
will be valuable for (i) diagnosis of under- or over-growth
phenotypic subtypes of ASD, (ii) selection of homogeneous
patient populations for more rigorously controlled studies, and
(iii) a potential biomarker that can be used to potentially
assess efficacy of clinical trials. We propose that broadly
stratifying patient populations in terms of under- or over-growth
phenotypes based on the following signaling pathways would
facilitate mechanistic and therapeutic insights into ASD, without
necessitating an impractical fine categorization by precise genetic
etiology.
Growth Factor Signaling
Neurotrophins, such as nerve growth factor (NGF) and brain-
derived neurotrophic factor (BDNF) were first identified
as target-derived survival factors. However, growing body
of evidence has indicated that neurotrophins regulate
many aspects of neuronal structure and function, including
neurodevelopment, differentiation, morphogenesis, and synaptic
plasticity (Poo, 2001; Reichardt, 2006). Subsequent research
over the past half century has revealed the existence of other
canonical neurotrophins, including neurotrophin-3 (NT-3),
and neurotrophin-4 (NT-4). Each of the four mammalian
neurotrophins binds to and activates one or more of the three
members of the tropomyosin-related kinase (Trk) family of
receptor tyrosine kinases (TrkA, TrkB, and TrkC), leading to
subsequent activation of phosphatidylinositol 3-kinase (PI3K),
phospholipase C (PLC), ERK1/2, and mTOR signaling (Chao
et al., 2006; Reichardt, 2006). Additionally, appropriate control of
neurotrophin signaling at multiple regulatory levels (epigenetic,
transcriptional, post-transcriptional, and post-translational) is
critical to physiological functions, such as cell fate decisions,
axon growth, and dendritic growth and pruning, and overall
neuronal network connectivity (Reichardt, 2006; Park and
Poo, 2013). Genetic knockout strategies and pharmacological
interventions reveal that many growth regulatory effects
of neurotrophins depend upon Trk signaling pathways
and subsequent activation of downstream cellular cascades
(Reichardt, 2006; Park and Poo, 2013). Consistent with their
potent roles as regulators of neuronal proliferation, survival,
differentiation, and morphogenesis, dysregulated neurotrophin
signaling has been implicated in neurodegenerative disorders,
such as Alzheimer’s and Huntington’s disease, and also
psychiatric disorders, including depression, substance abuse, as
well as autism (Tsai, 2005; Chao et al., 2006; Martinowich et al.,
2007; Nishimura et al., 2007; Gadow et al., 2009; Sadakata and
Furuichi, 2009).
Other trophic factors, such as glial-derived neurotrophic
factor (GDNF), vascular endothelial growth factor (VEGF), and
ciliary neurotrophic factor (CNTF), as well as insulin-like growth
factor (IGF) also induce pro-growth signaling pathways. Like
BDNF, NGF, NT-3, and NT-4, these additional trophic factors
also signal through receptor tyrosine kinases to elicit downstream
signaling cascades that promote growth in a variety of tissues,
including neurons (Junger and Junger, 1998; Ferrara et al.,
2003; Chao et al., 2006; Reichardt, 2006; Laviola et al., 2007).
Dysregulation in these trophic factors has been documented
in ASD, and extensive work in neurodegenerative disorders
has characterized their trophic and pro-survival effects in the
brain, including in motor neuron atrophy (IGF and CNTF),
neuropathies of the peripheral nervous system (NGF and NT-
3), Alzheimer’s disease (NGF, BDNF, IGF), diabetic retinopathy
(CNTF, BDNF), Huntington’s disease (BDNF, NT-3, NT-4),
Parkinson’s disease (BDNF, GDNF), and amyotrophic lateral
sclerosis (VEGF and IGF) (Hefti, 1994; Dawbarn and Allen,
2003; Gasparini and Xu, 2003; Zuccato and Cattaneo, 2009;
Weissmiller and Wu, 2012; Ola et al., 2013; Keifer et al., 2014).
The pronounced pro-growth and proliferative effects of these
neurotrophins and their downstream effectors, such as mTOR
and ERK1/2, make dysregulation in trophic factor cascades
excellent readouts for stratification of ASD into generally
overgrowth or undergrowth entities.
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mTOR
mTOR is a highly conserved and ubiquitously expressed
serine/threonine kinase that serves as an important regulator of
cellular growth, metabolism, and survival in both developmental
and disease states across a variety of tissue types. mTOR functions
in two heteromeric and functionally distinct protein complexes,
mTORC1 and mTORC2, which are embedded into complex
signaling networks. In the brain, mTOR integrates inputs from a
range of extracellular sources, including growth factors, guidance
cues, and nutrients (Takei and Nawa, 2014).
mTOR regulates many processes that are essential for
growth by serving as a nexus for controlling protein synthesis,
energy homeostasis, metabolism and actin cytoskeletal dynamics.
Studies of tumorigenesis strongly implicate mTOR activity as a
correlate of growth and metabolic status. Many familial cancer
syndromes result from mutations in genes encoding upstream
proteins that influence mTOR activation, including Tsc1/2,
PTEN, and neurofibromatosis type I (NF1) (Yuan and Cantley,
2008). Dysregulation of genes in this pathway has also been
linked to multiple disease conditions, including ASD, type II
diabetes, obesity, and neurodegeneration (Zoncu et al., 2011;
Laplante and Sabatini, 2012; Takei and Nawa, 2014).
Importantly, bidirectional changes in mTOR signaling have
also been shown to result in opposing downstream effects
on neuronal growth and morphogenesis. In mice, ablation
of mTOR or associated components that regulate mTORC1/2
assembly and signaling leads to embryonic lethality (Guertin
et al., 2006; Shiota et al., 2006). Conditional deletion of
both mTORC1 and mTORC2 in neural progenitors of the
developing CNS can cause microcephaly due to an overall
decrease in neuronal number and size as a result of reduced
neuronal progenitor proliferation and suppressed differentiation
of cortical neurons (Cloëtta et al., 2013; Thomanetz et al.,
2013; Ka et al., 2014). Conversely, enhanced mTOR signaling
following inactivation of upstream negative regulators (PTEN
and TSC1/2), or constitutive activation of positive regulators
(PI3K, Akt, and Ras), has been associated with macrocephaly,
neuronal hypertrophy, and increased soma size and dendritic
complexity of hippocampal neurons (Jaworski et al., 2005; Kwon
et al., 2006). These effects of mTOR activation on neuronal
and dendritic morphogenesis requires novel protein synthesis
(Jaworski et al., 2005).
mTOR-mediated regulation of protein translation has
garnered much interest in the field of ASD research. Substrates
of mTOR that are critically involved in the translation initiation
machinery, such as p70 ribosomal S6 kinase 1 (S6K1) and the
eukaryotic translation initiation factor 4E-binding proteins
(4E-BPs), are emerging as key players in autism pathogenesis
(Klann and Dever, 2004). Phosphorylation of S6K1 by mTORC1
promotes ribosomal biogenesis, translational initiation, and
elongation through a variety of effectors (Ma and Blenis, 2009).
Mice harboring a genetic deletion of S6K1 are significantly
smaller than wild-type counterparts. Certain protein synthesis-
dependent forms of synaptic plasticity which may represent
correlates of growth in adulthood, such as mGluR-LTD, have
been associated with increased phosphorylation and activation
of S6K1 (Antion et al., 2008).
Unphosphorylated 4E-BP2 inhibits cap-dependent protein
synthesis by sequestering the translation initiation factor eIF4E.
Phosphorylation of 4E-BP2 by mTORC1 leads to its dissociation
from eIF4E, thereby de-repressing its cap-binding activity and
enabling formation of the eIF4F translation initiation complex.
Deletion of 4E-BP2 or overexpression of eIF4E in vivo leads to
increased eIF4F complex formation, facilitated protein synthesis-
dependent long-term synaptic plasticity, elevated dendritic spine
density, and behavioral abnormalities reminiscent of ASD
(Banko et al., 2005, 2006; Gkogkas et al., 2013; Santini et al.,
2013).
Taken together, bidirectional changes in mTOR signaling lead
to opposite effects on protein synthesis, metabolism, and growth.
Therefore, measuring activity levels of mTOR or downstream
effectors of this cascade may serve as reliable indicators of altered
pro- or anti-growth states in the brain.
ERK1/2
ERK1/2 are paralogous members of the MAPK signaling cascade
with well-characterized roles in regulating growth at cellular
and organismal levels. The canonical MAPK/ERK pathway
transduces signals from cell surface receptors to the nucleus
through sequential phosphorylation steps. This pathway is
responsive to growth factors, chemokines, oxidative stress, and
cytokines (Lu et al., 2005; Byts et al., 2006; Samuels et al.,
2009; Hsieh et al., 2010). The ERK1/2 signaling cascade has
important roles in cellular proliferation, differentiation, and
apoptosis (Murphy and Blenis, 2006). In the nervous system,
activation of this pathway generally promotes excitation and is
involved in activity-dependent plasticity, long-term potentiation
(LTP), long term depression (LTD) and memory formation
(Satoh et al., 2011). Downstream targets of ERK1/2 signaling in
neurons govern processes such as dendritic spine stabilization,
modulation of ion changes and receptor insertion (Sweatt,
2004).
Recent genome-wide association studies (GWAS) and analysis
of copy number variations (CNV) have identified an enrichment
of MAPK/ERK signaling components in patients with autism
(Pinto et al., 2010). Furthermore, ERK1/2 activation is required
for the formation and stabilization of dendritic spines (Wu
et al., 2001; Goldin and Segal, 2003) and activation of ERK1/2
by growth factors has well-characterized functions in regulating
cell proliferation in the CNS (Sweatt, 2004; Samuels et al.,
2009). ERK1/2 plays a critical role in corticogenesis through
regulation of the cell cycle in proliferation of neural progenitor
cells. While both ERK1 and ERK2 are expressed highly in
the adult brain, ERK2 levels are higher than ERK1 (Samuels
et al., 2009). Additionally, only loss of ERK2 results in early
embryonic lethality in mouse models primarily through a failure
of normal placental and trophoblast development (Samuels et al.,
2009). Conditional knockout of ERK2 during the height of
cortical neurogenesis results in a decrease in neuron number and
subsequent increases in astrocyte number in the murine cortex.
This decrease reflects alterations in growth and proliferation
by a reduction in the number of cell divisions in intermediate
progenitor cells leading to decreased cortical thickness (Samuels
et al., 2008).
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The strongest evidence implicating disruption of ERK1/2
signaling in ASD comes from a number of single gene mutations
that are associated with autism including Tuberous sclerosis,
Fragile X syndrome, 16p11.2 (discussed in future sections in
this review) and NF1 all ultimately leading to activation of
ERK1/2. NF1 is a GTPase-activating protein (GAP) for Ras,
an upstream activator of ERK1/2. Mutations in NF1 cause
neurofibromatosis type 1, an autosomal inherited disorder with
a high frequency of hyper-proliferative schwannoma cancers.
More than 50% of individuals with mutations in NF1 also have
cognitive impairments and recent studies report a significant
increase in the incidence of ASD in NF1 patients (Marui et al.,
2004). In addition to the numerous monogenic forms of autism
implicating ERK1/2 activity in disease pathophysiology, the
inbred mouse strain BTBR, a model of non-syndromic autism,
shows an increase in phospho-ERK1/2 levels in the pre-frontal
cortex (Faridar et al., 2014).
ERK1/2 is a critical regulator of development and alterations
in ERK1/2 activity, either increased active phospho-ERK1/2 or
decreased phospho-ERK1/2, have been associated with autistic
features (Wang et al., 2012; Yufune et al., 2015). Interestingly,
a recent study conducted in mice suggests that there may be a
critical window for alterations in ERK1/2 activity to lead to the
development of ASD. The authors find that blockade of ERK1/2
signaling through administration of the MEK inhibitor SL327 at
postnatal day 6 leads to adult mice exhibiting common autistic
behavioral phenotypes, such as deficits in social interaction, as
well as increased apoptosis in the forebrain (Yufune et al., 2015).
However, inhibition of ERK1/2 at postnatal day 14 did not lead to
the development of autistic behaviors in these mice, suggesting
a critical window in development for regulation of ERK1/2
activity. Collectively, strong evidence from multiple biological
settings links ERK1/2 pathways to the regulation of growth states,
including proliferation and excitation.
Characterization of Genetically Defined
Models of ASD Based on Growth Readouts
This section reviews ASD of known genetic cause and the mouse
models of these ASD with reference to growth pathway correlates
(Table 1). The presented mouse models recapitulate many
phenotypes of human ASD, including dysregulation of neuronal
growth and development, synaptic transmission, neuronal
connectivity, and behavior. Although eachmousemodel does not
perfectly genocopy the human genetic variants that predispose
individuals to ASD, they present valuable resources for
mechanistic investigations into the genetic pathways underlying
aberrant neuronal growth. Moreover, given that several of these
models involve copy number variants (CNVs) as well as deletions
and duplications of a given chromosomal locus, these models
provide insights into how gain or loss-of-function can impact
the spectrum of neuronal growth phenotypes inherent in patients
with ASD. Mouse models of ASD of known genetic etiology will
be informative for diagnosis and future clinical studies that target
pathways of cellular growth that are dysregulated in individuals
with ASD.
TABLE 1 | Classification of well-established monogenic and copy number
variant models of ASD based on correlates of neuronal growth and
connectivity.
Genetic etiology Associated syndrome Synaptic or
neuronal growth
phenotype
Fmr1 Fragile X syndrome Overgrowth
TSC Tuberous sclerosis Overgrowth
PTEN N/A Overgrowth
MeCP2 loss-of-function Rett syndrome Undergrowth
MeCP2 gain-of-function MeCP2 duplication syndrome Overgrowth
AUTS2 Syndromic intellectual disability Undergrowth
16p11.2 microdeletion Non-syndromic ASD Overgrowth
16p11.2 duplication Non-syndromic ASD Undergrowth
22q11.2 microdeletion Non-syndromic ASD Undergrowth
Monogenic Models of ASD
Fragile X Syndrome
Fragile X syndrome (FXS) is the most common inherited cause
of ASD and intellectual disability, affecting approximately 1
in 4000 males and 1 in 8000 females worldwide (Peprah,
2012). Accounting for 2–6% of all cases of autism, FXS
is a neurodevelopmental disorder that is associated with an
expansion in a CGG trinucleotide repeat element in the 5′
UTR of the Fragile X Mental Retardation 1 (FMR1) gene.
The mutation leads to hypermethylation of the locus and
transcriptional silencing of FMR1, which subsequently leads to
a loss of production of its downstream gene product, Fragile X
Mental Retardation Protein (FMRP) (Penagarikano et al., 2007).
FMRP is localized in the soma and dendrites of neurons, where
it functions predominantly to suppress the translation of a subset
of mRNAs (Penagarikano et al., 2007). The anatomical, synaptic,
and molecular features of FXS have made this monogenic
disorder a classic model of developmental overgrowth in ASD.
FXS patients display intellectual disability and cognitive
impairments, developmental delay and physical features
consistent with overgrowth, such as macrocephaly, elongated
facial morphology, and enlarged ears (Chudley and Hagerman,
1987). Additional growth deficits include an increase in body
weight in a subset of FXS patients (Nowicki et al., 2007) and
macroorchidism, or enlarged testicles, in males following the
onset of puberty (Chudley and Hagerman, 1987). In postmortem
brain tissue isolated from FXS patients, studies have found
an overall increase in dendritic spine density as well as more
immature spine morphology (Irwin et al., 2001). FXS patients
and mouse models deficient in FMRP also display hallmarks
of brain morphology and function found in other genetic
causes of autism defined by overgrowth. These include an
early overabundance of synapses, brain hyperconnectivity,
and excessive basal and activity-responsive neuronal protein
synthesis (Dölen et al., 2007; Gibson et al., 2008; Pan et al., 2010).
In the central nervous system and the testis, two tissues in
which FMRP is known to be highly expressed (Penagarikano
et al., 2007), loss of FMRP function causes gross morphological
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abnormalities. For example, children with FXS andmice deficient
in FMRP display significantly increased hippocampal volume
(Kates et al., 1997; Shi et al., 2012). Specifically, structural
MRI methods show an increase in hippocampal volume from
P18–30 in Fmr1 KO mice (Shi et al., 2012). Another well-
described and reproducible growth defect observed in patients
and mouse models of FXS is macroorchidism. Fmr1 KO mice
display an elevation in testes weight that has been linked
to increased proliferation of supporting Sertoli cells during
embryonic development (Slegtenhorst-Eegdeman et al., 1998;
Dölen et al., 2007).
Accumulating reports further indicate a critical role for FMRP
function in the proper control of developmental timing. FMRP
deficiency leads to temporal delays in many developmental
settings, including the perinatal critical period for barrel cortex
plasticity (Harlow et al., 2010) and the switch in polarity of GABA
signals from depolarizing to hyperpolarizing (He et al., 2014).
Loss of FMRP also causes increased proliferation and abnormal
differentiation of neural stem and progenitor cells (Castrén et al.,
2005; Callan et al., 2010).
Abnormalities in dendritic spines are thought to be a central
feature of FXS, but the precise nature of the defect is still
controversial. Although there are several reports of altered spine
density and morphology in the Fmr1 KO mouse model, the
observed alterations appear to vary considerably depending on
the culture/staining methods, developmental age, brain region,
and mouse background strain (He and Portera-Cailliau, 2013).
More recent studies using in vivo two-photon microscopy to
image dendritic spine dynamics in intact neocortex from Fmr1
KO mice have revealed specific defects in spine turnover and
maturation that reflect a pro-growth state during development.
Cortical pyramidal neurons display abnormally high rates of
spine turnover and delayed stabilization of spines during early
postnatal development, coinciding with the critical period for
spine formation and plasticity in the neocortex (Cruz-Martín
et al., 2010; Pan et al., 2010).
At the functional level, Fmr1 KO mice exhibit network
hyperexcitability and an imbalance between excitation and
inhibition in neural circuits (Gibson et al., 2008; Gonçalves et al.,
2013). While excessive neuronal growth and delayed synaptic
maturation during critical periods for experience-dependent
plasticity in the brain can influence the wiring and functional
integrity of neural circuits, the exact outcome of such changes are
likely mediated in a cell type-specific manner. Therefore, future
studies need to examinemolecular readouts of growth in different
cell types in the brain, and in the context of specific functional
circuits.
Several studies using neuronal and peripheral tissues from
FXS patients and Fmr1 KO mice have investigated ERK1/2
phosphorylation status. Although results from these studies have
shown some discrepant findings, possibly due to the labile
nature of ERK1/2 phosphorylation, a number of reports have
shown elevated basal phospho-ERK1/2 (pERK1/2) levels in brain
tissues from Fmr1 KO mice and FXS patients (Michalon et al.,
2012; Wang et al., 2012). Inhibition of the ERK1/2 pathway
normalizes excessive hippocampal protein synthesis and also
alleviates certain behavioral abnormalities observed in Fmr1 KO
mice, including audiogenic seizure susceptibility (Wang et al.,
2012; Osterweil et al., 2013). Further, a phase I clinical trial of
the Ras-ERK1/2 inhibitor, lovastatin, conducted by Dr. Francois
Corbin’s group showed significant behavioral improvements in
FXS patients (Çaku et al., 2014).
In addition to hyperactive ERK1/2, another critical molecular
player that may contribute to pro-growth phenotypes in FXS
is dysregulated mTOR signaling. Although most analyses so
far have been conducted at older ages, elevated levels of
phospho-AKT, phospho-S6K, and active phospho-eIF4E have
been detected in brain tissue and peripheral blood lymphocytes
from FXS patients (Hoeffer et al., 2012). Similar hyperactivation
of several upstream and downstream components of the mTOR
cascade have been observed in brains of Fmr1 KO mice (Sharma
et al., 2010). Additionally, deletion of S6K in Fmr1 KO mice
rescues exaggerated hippocampal protein translation, aberrant
dendritic spine morphology and macroorchidism (Bhattacharya
et al., 2012). Normalizing elevated levels of PI3K enhancer
(PIKE), the upstream activator of PI3K-Akt-mTOR signaling,
in Fmr1 KO mice also normalizes dendritic spine density and
network hyperexcitability (Gross et al., 2015).
Hyperactivation of the ERK1/2 and mTOR pathways in FXS
has been generally linked to excessive global protein synthesis in
the brain. Auerbach et al. elegantly demonstrated that restoring
the optimal balance of intracellular signaling and downstream
protein synthesis may reverse synaptic and behavioral defects in
mouse models of FXS and TSC (Auerbach et al., 2011; Bhakar
et al., 2012). Changes in protein synthesis have become a focal
point in the study of ASD, and are one of multiple key cellular
readouts for growth state. It is worth noting, however, that global
upregulation or downregulation of mRNA translation may not
directly result in overgrowth or undergrowth phenotypes, which
are likely to depend upon the identity of the affected mRNAs.
For example, an overgrowth phenotype might also be achieved
by an alteration in the specificity of protein synthesis to increase
translation of pro-growth genes without any change in total
protein synthesis. The regulation of gene target selectivity in
translation may also play a role in the contribution of altered
protein synthesis to pro- or anti-growth phenotypes observed in
subtypes of ASD.
There is also evidence supporting dysregulation of upstream
activators of the ERK1/2 and mTOR pathways in autism,
including BDNF signaling through the TrkB receptor (Maija
Castrén and Castrén, 2014). TrkB mRNA has been identified as
a target for translational suppression by FMRP (Darnell et al.,
2011). While it is clear that BDNF/TrkB signaling is altered
in FXS, the precise effects of FMRP loss on spatiotemporal
expression patterns or activity of BDNF and the TrkB receptors
are currently unknown. Elevated catalytic TrkB expression has
been observed in undifferentiated neural progenitor cells from
Fmr1 KO mice (Louhivuori et al., 2011). BDNF expression in
the hippocampus varies with age in Fmr1 KO mice, with levels
significantly higher than wild-type controls at 2 months of age
(Uutela et al., 2012). However, alterations in BDNF expression
appear to differ by brain region (Louhivuori et al., 2011). Since
BDNF is known to establish pro-growth programs of gene
expression that are important for neuronal proliferation and
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morphogenesis, elevations in BDNF signaling may significantly
contribute to hypertrophic phenotypes observed in FXS (Poo,
2001; Reichardt, 2006).
Another line of evidence pointing to upregulated BDNF
signaling in FXS comes from recent studies demonstrating
aberrant increases in matrix metalloprotease-9 (MMP9) levels
in brains of FXS patients and Fmr1 KO mice (Gkogkas et al.,
2014). Elevated protein levels of MMP9 have also been detected
in plasma and amniotic fluid derived from FXS and ASD patients
(Dziembowska et al., 2013; Leigh et al., 2013).MMP9 is a protease
that can cleave pro-BDNF to mature BDNF in the hippocampus
(Mizoguchi et al., 2011) and developing neuromuscular junction
(Je et al., 2012). Two studies demonstrated that genetic and
pharmacological reduction of MMP9 levels ameliorates FXS-
associated anatomical and behavioral abnormalities (Gkogkas
et al., 2014; Sidhu et al., 2014). Treatment with a tetracycline
derivative, minocycline, ameliorates enhanced MMP9 levels and
significantly improves behavioral performance in Fmr1 KO mice
(Bilousova et al., 2009). In clinical trials, treatment of FXS
children and adults with minocycline has been found to be well-
tolerated and results in significant behavioral improvements, as
measured by the Clinical Global Impression Scale and ABC-C
Irritability Subscale (Paribello et al., 2010; Leigh et al., 2013).
Further, clinical responses to minocycline are correlated with
changes in plasma MMP9 levels (Dziembowska et al., 2013).
Together, these findings point to a potential involvement of the
BDNF/MMP9 axis in FXS pathogenesis that would be worth
exploring in future studies.
Collectively, work by several groups indicates that hyperactive
ERK1/2, mTOR, and BDNF pathways may contribute to
neuronal protein synthesis, growth, and connectivity defects in
FXS. Therefore, the molecular and biochemical signatures of FXS
are in accordance with its categorization as an overgrowth form
of ASD.
Tuberous Sclerosis
Tuberous sclerosis (TSC) is a neurodevelopmental disorder that
is caused by autosomal dominant mutations in the TSC1 or TSC2
tumor suppressor genes, which function as negative regulators
of the mTOR signaling cascade. Loss of TSC1/2 function which
enhances cell growth and promotes dysregulated metabolism
leads to non-malignant tumor formation in the skin, brain,
and other organs (Curatolo et al., 2008). Importantly, almost
50% of individuals with TSC also meet criteria for diagnosis
of ASD or intellectual disability (Curatolo et al., 2008; Jeste
et al., 2008). Most commonly used mouse models of TSC, such
as mice harboring heterozygous genetic deletions of Tsc1 or
Tsc2, exhibit phenotypes that recapitulate aspects of the human
disease, including synaptic dysfunctions, deficits in learning and
memory, and impaired social interactions (Goorden et al., 2007;
Ehninger et al., 2008; Sato et al., 2012; Tang et al., 2014).
Homozygous deletion of Tsc1 in postnatal forebrain neurons
using CaMKII-CRE Tsc1flox/flox mice leads either to lethality or
severe brain enlargement and neuronal hypertrophy in animals
surviving to 3months of age (Ehninger et al., 2008). Initial studies
characterizing the function of TSC1/TSC2 complexes in the brain
identified important roles in regulating neuronal growth and
neural network homeostasis. In particular, complete in vivo loss
of Tsc1 in post-mitotic neurons induces ectopic axon formation
(Choi et al., 2008), enlarged and dysplastic neuronal morphology
(Meikle et al., 2007), and network hyperexcitability due to
weakened functional synaptic inhibition (Bateup et al., 2013).
Recent work has also demonstrated that Tsc1 and P20-P30 Tsc2
deficient mice display reduced pruning of dendritic spines during
a critical period in development, giving rise to increased spine
density at later postnatal ages. Tang et al. attributed the observed
failure of developmental spine pruning in mouse models of TSC
to a deficit in mTOR-dependent macroautophagy (Tang et al.,
2014).
Importantly, many of the aforementioned hypertrophic
phenotypes of TSC loss-of-function are ameliorated by
treatment with the mTORC1 inhibitor, rapamycin, suggesting
that hyperactive mTOR signaling plays a critical role in neural
overgrowth and hyperconnectivity defects in TSC. For most
studies conducted, rescue of synaptic or behavioral abnormalities
has beenmost successful if rapamycin is administered chronically
beginning at early postnatal ages. This further supports the
possibility that early mTOR hyperactivation may be the primary
insult that triggers downstream effects on neuronal growth,
development, and excitability. Although mTOR signaling
appears to be persistently increased following TSC1/2 deficiency,
secondary pathways may be engaged to maintain synaptic
and behavioral defects into adulthood. Therefore, it remains
to be assessed whether synaptic overgrowth and associated
dysfunctions may be reversed by mTOR inhibition later in
adulthood.
In accordance with known functions of mTOR in the
regulation of mRNA translation, hyperactivation of this pathway
would be expected to enhance global protein synthesis.
Unexpectedly, adult Tsc2 haploinsufficient mice exhibit basal
suppression of hippocampal protein synthesis (Auerbach et al.,
2011). While examination of mRNA translation at early postnatal
ages is required, the reported reduction in basal protein synthesis
in adult Tsc2 deficient mice could reflect the tight homeostatic
regulation of mTOR signaling. Work in non-neuronal systems
has found that long-term hyperactivation of mTOR can evoke
compensatory downregulation of upstream signaling factors
through an inhibitory feedback loop (Hay, 2005). For example,
murine embryonic fibroblast cultures derived from Tsc2 null
mice exhibit increased mTOR activation, but reduced upstream
PI3K-Akt signaling (Zhang et al., 2003). The contribution of
developmental and homeostatic changes in growth pathway
readouts further underscore the importance of focusing on early
developmental ages for the classification of ASD subtypes.
Recent studies have also demonstrated that TSC1/2 may
interact with theMAPK/ERK signaling cascade. This relationship
was first appreciated in clinical studies which revealed
that components of the ERK1/2 pathway are constitutively
activated in TSC-associated brain lesions and tumor cell lines
(Govindarajan et al., 2003; Ma et al., 2005, 2007). Upregulated
ERK1/2 signaling has been observed in the 1RG model of
TSC, which recapitulates human deletion mutations that
disrupt TSC1/2 complex function by interfering with Tsc2
GAP activity (Chévere-Torres et al., 2012). The authors of the
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same study reported no differences in ERK1/2 phosphorylation
in hippocampi from Tsc1 (CamKII-CRE Tsc1+/fl) and Tsc2
(CamKII-CRE Tsc2fl/fl) mutant mice as compared to wild-type
controls. However, this experiment was performed in adult
animals where compensatory changes could have occurred, and
therefore, more thorough analysis of phospho-ERK1/2 levels
throughout development may be required.
TSC2 has, itself, also been implicated as a direct target of
ERK1/2 kinase activity, wherein phosphorylation of TSC2 by
ERK1/2 results in dissociation of the TSC1/2 tumor suppressor
complex and subsequent disinhibition of mTOR-dependent
effects on growth, proliferation, and protein synthesis (Ma et al.,
2005). Although these studies were conducted in the context of
tumorigenesis, this mechanism may be conserved in the nervous
system as well. The fact that TSC1/2 serves as an important node
of cross-talk and convergence between the ERK1/2 and mTOR
signaling cascades might explain how changes in components
of both pathways can produce a dysregulated growth state in
many syndromic and non-syndromic forms of ASD. Based on
the aforementioned phenotypes resulting from mutations in the
TSC tumor suppressor, we propose that ASD patients with TSC
loss-of-function represent an example characterized by neuronal
overgrowth phenotypes.
Phosphate and Tensin Homolog (PTEN)
The tumor suppressor gene PTEN is a dual protein and lipid
phosphatase critical for modulating cellular growth, proliferation
and survival. PTEN is a major inhibitor of the highly conserved
PI3K-Akt signaling pathways, and regulates diverse cellular
processes, including metabolism, survival, proliferation, growth,
and motility (Worby and Dixon, 2014). The tumor suppressor
functions of PTEN have been most thoroughly described in the
context of cancers, such as those of the skin, endometrium,
prostate and central nervous system (Chalhoub and Baker, 2009).
Mounting evidence has documented a role for PTEN in disorders
of nervous system function, including ataxia (Backman et al.,
2001), seizures (Backman et al., 2001), mental retardation (Varga
et al., 2009; McBride et al., 2010), and autism (Varga et al.,
2009; Zhou and Parada, 2012). Individuals with germline PTEN
mutations are not only prone to cancer, but many of these
individuals are also at risk of developing autism with comorbid
macrocephaly (Butler et al., 2005; Clipperton-Allen and Page,
2014).
To better understand the cellular and molecular mechanisms
by which dysregulated PTEN signaling may predispose
individuals to macrocephaly and ASD, multiple groups have
genetically engineered PTEN-deficient mice. These studies have
shown that mice lacking PTEN in differentiated neurons exhibit
macrocephaly, regional hypertrophy, increased soma, dendritic
and axonal growth, ectopic axons and dendrites, and increased
spine density (Backman et al., 2001; Kwon et al., 2001; Greer
and Wynshaw-Boris, 2006; Fraser et al., 2008; Amiri et al.,
2012). Additionally, these mice display classic autism-related
behavioral abnormalities including impaired social interaction,
learning deficits, hypersensitivity to acoustic stimuli, increased
seizure susceptibility, and exaggerated anxiety-like behaviors
(Kwon et al., 2006). Additionally, loss of PTEN in adult
hippocampal stem cell populations was shown to accelerate stem
cell proliferation rates and activate PI3K/AKT/mTOR/GSK3B
signaling pathways to promote a pro-growth phenotype.
Neurons differentiated from these stem cells exhibit dendritic
and axonal hypertrophy (Amiri et al., 2012), consistent with
PTEN’s role as a suppressor of growth in multiple systems.
Many of the neuronal hypertrophic phenotypes and behavioral
abnormalities associated with loss of PTEN can be rescued by
pharmacological inhibition of downstreammTOR signaling with
rapamycin, but surprisingly not by loss of S6K1, a downstream
effector of ERK1/2 (Kwon et al., 2003; Chalhoub et al., 2006; Zhou
et al., 2009). Thus, future research is required to determine the
precise mechanisms by which rapamycin-mediated inhibition of
mTOR is able to rescue the pro-growth phenotypes observed in
PTEN deficient neurons.
Methyl-CpG-binding protein
Methyl-CpG-binding protein (MeCP2) is a regulator of gene
expression which is present in cells throughout the body, but
is particularly abundant in the brain. MeCP2 provides an
interesting case in which the available evidence indicates that
loss of MeCP2 (Rett Syndrome) can produce an “undergrowth”
entity, while excess MeCP2 (MeCP2 duplication syndrome)
conversely results in a presentation consistent with underlying
“overgrowth.” Rett Syndrome (RTT), in 95% of cases, is
caused by loss-of-function mutations in the X-linked MeCP2
and is predominately seen in females (around 1/10,000 live
births) as these mutations in males lead to perinatal lethality
(Amir et al., 1999). Behaviorally, children with Rett syndrome
display some core features of autism, including repetitive
behaviors and poor communication skills. MeCP2 duplication
syndrome, which is caused by duplication of the MeCP2 gene,
presents with intellectual disability, seizures, motor dysfunction,
developmental delay and autistic behavior (Ramocki et al., 2010).
Patients with Rett Syndrome appear to develop normally
until 6–18 months of life and then exhibit dramatic
motor/autonomic deterioration, and deceleration of head
growth with microcephaly evident by the second year of life.
MeCP2 plays a role in synaptic maturation and pruning in
development as well as the maintenance of dendritic arbors in
adulthood (Schüle et al., 2008; Matijevic et al., 2009; McGraw
et al., 2011; Baj et al., 2014). Characterization of postmortem
brain tissue obtained from patients with RTT found a 12–34%
reduction in brain weight and volume. There is a decrease in
hippocampal spine density, decreased dendritic branching,
reduction in neuronal size, and reduced white matter volume.
However, there is no obvious degeneration present in RTT brains
suggestive of MeCP2’s role in regulation of postnatal neuronal
growth and not in neurodegeneration (Reiss et al., 1993; Jellinger,
2003). A number of these phenotypes are recapitulated in the
male Mecp2-null mice which display normal development until
3–8 weeks of age but begin a sharp decline, exhibiting tremors,
difficulty in locomotion and hypotonia. While there are no
obvious structural abnormalities present in the MeCP2 null
mice, their brains are reduced in size and have a smaller, denser
composition of neurons as compared to wild-type controls.
While male MeCP2 null mice often die within 6–10 weeks,
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female heterozygotes remain viable until 4–6 months and at
this point begin to exhibit RTT-like symptoms (Guy et al.,
2001; Ricceri et al., 2008; Chen et al., 2013). In an additional
mouse model of RTT, a truncation of MeCP2 at amino acid 308
(MeCP2308/Y) leads to a less severe progression of neurological
phenotypes but also mirrors deficits found in RTT patients.
Due to the rare occurrence of MeCP2 duplication syndrome,
very little analysis on the morphology of post-mortem brain
tissue has been reported; however, some evidence suggests
macrocephaly in patients with MeCP2 duplication syndrome
(Lugtenberg et al., 2009). The MeCP2 duplication mouse model
(2-fold overexpression of human MeCP2) displays an initial
enhancement of synaptic plasticity and motor and contextual
learning. At around 20 weeks of age, however, these transgenic
mice develop seizures and motor deficits and eventually die
around 1 year of age (Collins et al., 2004; Luikenhuis et al., 2004).
While there are conflicting reports about the effects of MeCP2
overexpression on synaptic density, there is some evidence to
suggest that MeCP2 duplication leads to an increased density
of excitatory synapses (Zhou et al., 2006; Chao et al., 2007;
Chapleau and Pozzo-Miller, 2012). Misexpression of MeCP2 is
also associated with other neuropsychiatric disorders ranging
from intellectual disability, schizophrenia, Angelman-like
syndrome and autism (Chahrour and Zoghbi, 2007).
MeCP2 plays a complex role in regulating the gene expression
of multiple growth control pathways, and the cellular outcomes
downstream of these genes. Current research, which is detailed
in other reviews (Cheng and Qiu, 2014), has shown that MeCP2
can regulate transcription both as a transcriptional repressor, as
well as a transcriptional activator through CREB1 recruitment
(Chahrour and Zoghbi, 2007). Induced neurons (IN) have
been used recently to show that MeCP2-deficiency particularly
reduces the levels of activity-dependent neuronal genes which
are important for the promotion of growth and plasticity (Li
et al., 2013), including BDNF and IGF1 (Castro et al., 2014).
In vitro MeCP2 has been shown to bind the BDNF promoter
region and repress its transcription when the neuron is not
active. Following neuronal activity, MeCP2 is phosphorylated at
serine 421 and removed from the promoter region, allowing for
transcription of BDNF to occur (Chen et al., 2003; Martinowich
et al., 2003; Zhou et al., 2006). The story in vivo, however, is
more complex. In the MeCP2 -/y mice, Chang et al., discovered
that overall BDNF levels are reduced, most likely due to reduced
cortical activity present in the MeCP2 -/y brain (Dani et al., 2005;
Chang et al., 2006). Importantly, the authors demonstrated that
increasing expression of BDNF within the forebrain of MeCP2 -
/y mice rescues motor function and increases lifespan, suggesting
an important functional interaction between this neurotrophic
factor and MeCP2. In accordance with this result, loss of MeCP2
has also been reported to depress levels of activated pERK1/2, and
activation of the Ras-ERK1/2 pathway by MeCP2 to be required
for the promotion of neuronal differentiation by MeCP2 (Sweatt,
2004). MeCP2-deficiency is also reported to lower ribosomal
RNA levels and to reduce protein synthesis (Li et al., 2013)
consistent with an undergrowth phenotype. Interestingly, recent
work provides evidence that MeCP2 interacts with DGCR8,
a component of nuclear microRNA (miRNA) processing, and
leads to suppression of pri-miRNA processing (Cheng et al.,
2014). Effects on miRNA biogenesis could provide an additional
regulatory mechanism by which loss ofMeCP2 alters not only the
quantity, but also the specificity of protein synthesis. Collectively,
the cellular and molecular signature of Rett syndrome is
consistent with its classification as an undergrowth type ASD,
while MeCP2 duplication syndrome is more appropriately
categorized as an overgrowth phenotype based on available
data.
Autism Susceptibility Candidate 2
The autism susceptibility candidate 2 (AUTS2) was initially
suspected to be associated with ASD found in a pair of
monozygotic twins which had a de novo balanced translocation
which disrupted the AUTS2 locus (Sultana et al., 2002). It has
been reported that a subset of patients harboring deletions
within exonic regions of AUTS2 present with a short stature,
facial dysmorphism, and microcephaly (Beunders et al., 2013).
Given these phenotypes, AUTS2 mutations are thought to lead
to predominately “undergrowth” phenotypes. Since the initial
identification of the AUTS2 locus, there have been over 30
additional individuals with cognitive disorders ranging from
ASD to epilepsy, attention deficit disorder, intellectual disability
and developmental delay harboring disruptions in both the
coding and noncoding regions of the AUTS2 locus (Kalscheuer
et al., 2007; Bakkaloglu et al., 2008; Glessner et al., 2009a; Elia
et al., 2010; Pinto et al., 2010; Ben-David et al., 2011). Given
that alteration of AUTS2 levels results in a myriad of neuronal
deficits, it is not surprising that AUTS2 is highly expressed in
developing brain regions important for higher order cognitive
functions.
The function of AUTS2 had preliminarily been explored in
the model system Danio rerio while the recent development
of a mouse loss-of-function model has begun to elucidate
the function of the AUTS2 gene product. The function of
AUTS2 has been recently addressed in animal models of
perturbation in AUTS2. In zebrafish, reductions of AUTS2
by morpholinos knockdown results in microcephaly, reduced
mobility and decreases in the number of neurons (Beunders
et al., 2013; Oksenberg and Ahituv, 2013). The Auts2 KO
mouse model also results in reduction in size and these mice
also display developmental delays, motor deficits, and altered
communications as assayed by pup ultrasonic vocalizations
(USVs) (Gao et al., 2014). This microcephaly phenotype is also
observed in mice and human patients with AUTS2 disruptions
suggesting a critical role for AUTS2 in neurodevelopment and
growth (Beunders et al., 2013).
Previous research has shown AUTS2 to be highly expressed
in neurons. The cytoplasmic pool of AUTS2 has been shown
to regulate neurite outgrowth and migration through the
regulation of the Rho family of GTPases (Hori et al., 2014).
Bidirectional alterations of AUTS2 levels in cortical neurons
lead to opposing phenotypes in neurite growth. Cortical neurons
which have shRNA knockdown of AUTS2 (introduced through
in utero electroporation at E15.5 and cultured to DIV 2-6)
display decreases in dendrite length and branch number whereas
overexpression in primary hippocampal neurons (at DIV 4)
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leads to increase in neurite elongation (Hori et al., 2014).
Nuclear populations of AUTS2 have been shown to play a role
in regulation of chromatin dynamics through its interaction
with PRC1, highlighting its potential role in regulation of
transcription (Gao et al., 2014). One interesting finding from
Gao et al. hints at a potential interaction between AUTS2 and
signaling pathways involved in growth. The authors find that
AUTS2 binds to the promoter regions of factors implicated in
growth including TSC2, IGFR, and k-Ras as seen through a ChIP-
seq performed inmouse brains. This is suggestive of amechanism
by which disruption of AUTS2 could lead to disruption of
neuronal growth and the “undergrowth” phenotype described in
human patients and animal models of AUTS2 mutations. While
current research has started to address the function of AUTS2 in
neuronal growth and development, much work needs to be done
to determine the molecular mechanism by which AUTS2 leads to
the pathogenesis of autism.
Copy Number Variant Models of ASD
16p11.2 Copy Number Variation
CNV at the human chromosome 16p11.2 locus is among the
most common risk variants associated with ASD, accounting for
approximately 0.5–1% of all cases (Malhotra and Sebat, 2012).
In fact, duplications and deletions in this ∼600 kB region of
16p11.2 have been linked to a number of neurodevelopmental
and psychiatric conditions, including intellectual disability,
schizophrenia, epilepsy, bipolar disorder, and obesity (Weiss
et al., 2008; McCarthy et al., 2009; Shinawi et al., 2010; Walters
et al., 2010; Zufferey et al., 2012). Several reports indicate that
reciprocal phenotypes occur as a result of deletion or duplication
of the approximately 27 protein-coding genes found in the
affected region. Therefore, 16p11.2 CNVs present a uniquemodel
to explore the effects of altered dosage of genes within this region
on underlying growth pathway correlates.
In humans, there is accumulating evidence supporting the
presence of pro-growth phenotypes in deletion carriers and anti-
growth features in duplication carriers. For instance, 16p11.2
microdeletion is linked to macrocephaly, whereas duplication
of this locus has been associated with microcephaly (Shinawi
et al., 2010). A recent study comparing global brain differences
between child carriers of 16p11.2 deletion (8.1 ± 3 years) and
duplication (7.8 ± 5 years) identified a strong dose-dependent
influence of CNV on brain volume. In deletion carriers, global
measures of gray and white matter volume, along with volumes
of certain subcortical structures such as the thalamus, were found
to be significantly elevated as compared to typically developing
controls. In contrast, these measures were altered in the opposite
direction in the case of duplication carriers (Qureshi et al.,
2014).
CNVs at 16p11.2 also confer highly penetrant and opposing
effects on body mass index (BMI). Parallel to the effects observed
with head size, deletion of this region often results in early-
onset obesity, while duplication is associated with significantly
reduced postnatal body weight and BMI (Jacquemont et al.,
2011). Importantly, a study that analyzed the co-occurrence of
head size and BMI phenotypes observed a higher incidence
of the 16p11.2 deletion among cohorts ascertained for both
developmental delay and obesity (2.9%), as opposed to cohorts
assessed for either outcome alone (0.6 and 0.4%, respectively)
(Walters et al., 2010). A potential avenue for future investigation
in mouse model systems is to test the involvement of common
molecular pathways in both neuronal and somatic growth defects
in 16p11.2 CNVs.
In order to systematically assess the effects of this CNV
on development and behavior, two independent groups, Horev
et al. and Portmann et al., utilized chromosome engineering
approaches to develop mutant mouse models harboring deletion
(df/+) and/or duplication (dp/+) of the conserved syntenic
region on chromosome 7 (Horev et al., 2011; Portmann et al.,
2014). Characterization of adult df/+ and dp/+ mutants has
revealed dose-dependent effects on expression of most genes
within the engineered interval, as well as opposing phenotypes
in certain neuroanatomical measures, including mild reciprocal
volumetric changes across multiple brain regions in adulthood
(Horev et al., 2011).
However, currently available mouse models of 16p11.2 CNVs
may not accurately recapitulate head and body size phenotypes
observed in human carriers. Despite expected changes in
expression of genes in the deleted interval, df/+mutants
display decreases in postnatal body weight (Portmann et al.,
2014; Pucilowska et al., 2015) and mild reductions in overall
brain volume that persist into adulthood (Horev et al., 2011;
Portmann et al., 2014; Pucilowska et al., 2015). Therefore, more
detailed phenotypic characterization of 16p11.2 CNV mouse
models is required in order to pinpoint the cause for this
discrepancy.
The gene, MAPK3, which encodes ERK1 is located within
the 16p11.2 region and has garnered interest with respect to
molecular phenotypes associated with this CNV. However, there
have been conflicting reports on the effect of 16p11.2 deletion,
and consequent ERK1 deficiency, on overall ERK1/2 activity.
When ERK1/2 activity is measured as a ratio of phosphorylated to
total ERK1/2 levels, studies have reported contradicting findings.
One group observed decreases in ERK1/2 activity, which were
correlated with decreased overall protein synthesis (Tian et al.,
2015). On the other hand, Pucilowska et al., found a paradoxical
upregulation of ERK1/2 activation (Pucilowska et al., 2015).
Inconsistencies in reports may necessitate the use of ERK1/2
reporters to accurately assay ERK1/2 catalytic function in mouse
models of 16p11.2 CNVs. Elucidating ERK1/2 pathway readouts
in 16p11.2 CNVs is further complicated by the fact that a gene
known to function as a negative regulator of ERK1/2, known
as major vault protein (MVP), is also found within the 16p11.2
locus (Liang et al., 2010). Therefore, further studies need to be
conducted in order to ascertain the impact of 16p11.2 CNVs on
readouts of ERK1/2 activity.
22q11.2 Copy Number Variation
Several reports have described the co-occurrence of autism in
subjects with chromosome 22 abnormalities including trisomy
22, translocation 20/22, 22q11.2 deletion, 22q11.2 duplication,
ring chromosome 22, and 22q13.3 deletion (Mukaddes and
Herguner, 2007). In 22q11.2 microdeletion (22q11.2DS;
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velocardiofacial syndrome, Digeorge syndrome), a syndrome
characterized by either a 1.5 or 3 megabasepair deletion of 22q11,
roughly one third of individuals develop a form of schizophrenia
and a smaller fraction (∼10–20%) display developmental delays
and learning disabilities characteristic of autism. In addition to
microdeletion at the 22q11.2 locus, genome-wide assays for copy
number variants have also identified significant enrichment of
22q11.2 duplication in unrelated ASD patients (Marshall et al.,
2008; Glessner et al., 2009b).
Although neuroimaging studies of patients with 22q11.2DS
report a wide range of abnormalities in both brain structure
and function, which are consistent with neuronal undergrowth
phenotypes, the literature remains relatively inconsistent
regarding differences in specific neuronal regions or structures.
Thus, direct correlations between these structural changes and
behavior are unable to be made at this time. These different
conclusions may be due to the use of different protocols for
measuring or normalizing volumes in studies that should
be replicated with larger cohorts (Karayiorgou et al., 2010).
However, in a meta-review on 22q11.2DS, when Karayiorgou
et al. examined those findings that have been replicated by
at least two independent research groups in at least two
separate and independent studies, they observed a pattern of
neuroanatomical abnormalities associated with undergrowth
phenotypes in patients with 22q11.2DS, both with and without
psychosis (Karayiorgou et al., 2010). These changes include
larger ventricles, reduced brain size, and volumetric reductions
of parietal lobes, hippocampus, cerebellum, reduced cortical
thickness, and lateral cortical thinning (Xu et al., 2010; Drew
et al., 2011a). Recent data modeling the 22q11.2 deletion
in rodents has revealed that a significant number of these
anatomical findings from 22q11.2 patients, including impaired
circuitry and reduced regional volumes of brain structures that
are critical to autism, are reliably recapitulated in the brains of
mice modeling this human disorder (Sigurdsson et al., 2010;
Drew et al., 2011a; Ellegood et al., 2014).
The 22q11.2DS mouse displays neuronal undergrowth,
dysregulated synaptic plasticity, and impaired neuronal circuit
formation, which are associated with abnormal behavioral
outcomes (Karayiorgou et al., 2010; Drew et al., 2011b;
Ellegood et al., 2014); however, the precise genetic mechanisms
underlying this phenotype remain unknown. This region of
human chromosome 22q11 contains 16 protein coding genes,
many of which have been shown to regulate cellular growth and
proliferation, such as TBX1, RTN4R, and ZDHHC8 (Yagi et al.,
2003; Mukai et al., 2008; Borrie et al., 2012); however, for the
purposes of this review, we will focus on another gene found
within this locus, DGCR8, since deletion of DGCR8 in mouse
models has revealed neuronal undergrowth that is able to be
rescued by enhanced trophic signaling.
DGCR8 positively regulates the maturation of miRNAs,
a recently discovered class of small, highly evolutionarily
conserved regulatory RNAs, which inhibit the translation
of near-complementary target mRNAs (Han et al., 2006).
Individuals with hemizygous expression of DGCR8, as found
in 22q11.2 deletion patients, would thus have impaired miRNA
biogenesis and reduced inhibition of target protein synthesis,
while those with 22q11.2 microduplication will have increased
DGCR8 gene dosage (Xu et al., 2010). In mice with DGCR8
haploinsufficiency, there is reduced basal dendritic complexity
(fewer branch points, less intersections, and decreased overall
dendritic length), decreased hippocampal neurogenesis, and
significant cognitive and behavioral deficits, consistent with the
neuronal undergrowth phenotype present in individuals with
22q11.2 microdeletion (Schofield et al., 2011; Ouchi et al.,
2013). Although it remains unknown as to whether or not
these neuronal growth deficits and behavioral abnormalities are
a direct consequence of reduced miRNA levels and enhanced
translation of these miRNA target genes, subsequent experiments
revealed that many of these deficits can indeed be rescued by
exogenous application of insulin-like growth factor 2 (Igf2),
a gene that is reduced in DGCR8-deficient animals by an
unknown mechanism (Ouchi et al., 2013). It should also be
noted that while expression of a phosphomimetic DGCR8 (which
mimics phosphorylation by kinases such asMAPK/ERK) induces
a pro-growth miRNA signature in a heterologous cell line
(Herbert et al., 2013), it remains unknown whether or not the
phosphorylation status of DGCR8 could serve as a diagnostic
biomarker for cases of autism characterized by aberrant
growth.
Conclusions
Relevance for Future Clinical Research and Trials
A compelling avenue of investigation is to design therapeutics
that effectively target pathways controlling neuronal growth in
ASD. Recent studies have allowed us to make significant progress
in understanding the nature of neuronal growth defects in ASD.
It remains a significant question in the field as to whether growth
defects are causal to the development and pathogenesis of ASD.
There are two lines of evidence that suggest that this may be the
case (i) growth abnormalities emerge early in the pathogenesis of
the disease, and (ii) manipulations and interventions that target
growth-related pathways not only ameliorate growth defects but
also lead to improvements in behavior.
For therapies to yield maximal success, the initial
identification and design should consider whether the form
of ASD being treated could be generally classified as overgrowth
or undergrowth. This sub-classification of growth phenotypes
in ASD is critical as the same drug is unlikely to be effective
under both circumstances. Aside from obvious growth defects
such as macrocephaly and microcephaly, more subtle growth
phenotypes might prove to be difficult to diagnose early in
development. Ultimately, development of a biomarker that
serves as a readout for growth status in ASD would be necessary
in order to facilitate early detection and proper intervention.
Possible development of biomarkers could include components
of growth pathways highlighted in this review, such as ERK1/2,
mTOR, and neurotrophic factors.
Relevance for Future Research Efforts
Proper growth of functional neural circuits requires highly
orchestrated control of intracellular signaling cascades and gene
expression. These changes in neuronal growth depend upon
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the specific composition of gene regulatory networks present
not only within each cell type, but within subcellular regions
of a given neuron that give rise to the various neuronal
processes, such as axons, dendrites, and spines, structures that
are often dysregulated in forms of autism characterized by over-
or undergrowth. Although CRE-driver lines have been highly
informative for our understanding of cell type specific changes
in behavior, gene expression, patterns of neuronal growth, and
connectivity across various brain regions between wild-type mice
and diseasemodels, development of CRE-drivers requires a priori
knowledge of the specific gene expression patterns unique to
each cell type. Even within cells identified by such a CRE-
driver system, there exists considerable heterogeneity in terms of
gene expression. Each of the human brain’s billions of neurons
is unique not only in terms of its activity signature but also
within the complex three-dimensional spatial environment of
the brain that permits unique connectivity for each neuron.
For these reasons, we predict that future single cell analyses
of gene expression across ensembles of cells from wild-type
controls and disease models will transform our understanding of
these highly complex cells and gain better mechanistic insights
into the signaling pathways that underlie over- or under-growth
phenotypes in ASD.
Many large-scale ASD studies have now been conducted,
which have included mixed patient populations, with variations
in multiple critical factors including age, diagnosis, and symptom
severity. However, it has remained difficult to extract meaningful
conclusions from these studies, in part, since molecular
changes are likely to be different among forms of ASD with
differing underlying etiologies. Identifying common molecular
pathways that are dysregulated among various genetic causes
of ASD is an important step in effectively stratifying ASD
into endophenotypes from which therapeutic responses can be
more readily anticipated. Shrinking the heterogeneity of the
disorder would also make the study of ASD more tractable,
allowing investigations in monogenic mouse models to be more
appropriately applied to other genetic forms of ASD. Utilizing
overgrowth and undergrowth phenotypes (Figure 1) as a basis
for this stratification is useful since these phenotypes are present
across multiple genetic causes of ASD and occur early in the
development of disease.
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